Floatz logo

Ralimetinib

Epithelial Ovarian Cancer

Eli Lilly and CompanySmall moleculePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

245 Active assets in the Epithelial Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Ralimetinib is also rated in:

adult glioblastomaDormant
CCC
Indicative ·
52 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
51 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →